Switch theme
Sign up to access all valuation multiples
Medartis Holding AG is a medical device company. The company's product profile is divided into APTUS products, StealthFix Products, and MODUS products. APTUS includes products for Hand, Wrist, Elbow, Shoulder, and Foot. MODUS comprises products for the mandible. Geographically, it derives the majority of its revenue from EMEA and also has a presence in APAC, USA, LATAM, and North America.
1997
876
LTM Revenue $272M
LTM EBITDA $47.1M
$1.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Medartis has a last 12-month revenue of $272M and a last 12-month EBITDA of $47.1M.
In the most recent fiscal year, Medartis achieved revenue of $240M and an EBITDA of $28.7M.
Medartis expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Medartis valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $207M | $240M | XXX | XXX | XXX |
| Gross Profit | $152M | $169M | XXX | XXX | XXX |
| Gross Margin | 73% | 71% | XXX | XXX | XXX |
| EBITDA | $13.2M | $28.7M | XXX | XXX | XXX |
| EBITDA Margin | 6% | 12% | XXX | XXX | XXX |
| Net Profit | $7.7M | -$6.5M | XXX | XXX | XXX |
| Net Margin | 4% | -3% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Medartis's stock price is CHF 71 (or $80).
Medartis has current market cap of CHF 961M (or $1.1B), and EV of CHF 955M (or $1.1B).
See Medartis trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.1B | $1.1B | XXX | XXX | XXX | XXX | $0.84 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Medartis has market cap of $1.1B and EV of $1.1B.
Medartis's trades at 4.0x LTM EV/Revenue multiple, and 22.9x LTM EBITDA.
Analysts estimate Medartis's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Medartis and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.1B | XXX | XXX | XXX |
| EV/Revenue | 4.5x | XXX | XXX | XXX |
| EV/EBITDA | 37.6x | XXX | XXX | XXX |
| P/E | 1552.8x | XXX | XXX | XXX |
| P/E/Growth | 3.2x | XXX | XXX | XXX |
| EV/FCF | 814.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpMedartis's NTM/LTM revenue growth is 17%
Medartis's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.2M for the same period.
Over next 12 months, Medartis's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Medartis's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Medartis and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 16% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 12% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 117% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 29% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.3M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 46% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 16% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 12% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 74% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Medartis acquired XXX companies to date.
Last acquisition by Medartis was XXXXXXXX, XXXXX XXXXX XXXXXX . Medartis acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Medartis founded? | Medartis was founded in 1997. |
| Where is Medartis headquartered? | Medartis is headquartered in Switzerland. |
| How many employees does Medartis have? | As of today, Medartis has 876 employees. |
| Is Medartis publicy listed? | Yes, Medartis is a public company listed on SWX. |
| What is the stock symbol of Medartis? | Medartis trades under MED ticker. |
| When did Medartis go public? | Medartis went public in 2018. |
| Who are competitors of Medartis? | Similar companies to Medartis include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Medartis? | Medartis's current market cap is $1.1B |
| What is the current revenue of Medartis? | Medartis's last 12-month revenue is $272M. |
| What is the current EBITDA of Medartis? | Medartis's last 12-month EBITDA is $47.1M. |
| What is the current EV/Revenue multiple of Medartis? | Current revenue multiple of Medartis is 4.0x. |
| What is the current EV/EBITDA multiple of Medartis? | Current EBITDA multiple of Medartis is 22.9x. |
| What is the current revenue growth of Medartis? | Medartis revenue growth between 2023 and 2024 was 16%. |
| Is Medartis profitable? | Yes, Medartis is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
